{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T17:50:51Z","timestamp":1789321851039,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-024-00993-9","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T23:28:56Z","timestamp":1733959736000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Challenging the Standard Immunogenicity Assessment Approach: 1-Tiered ADA Testing Strategy in Clinical Trials"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4735-3926","authenticated-orcid":false,"given":"Ching-Ha","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"McAfee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Speaks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Simeone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Stefan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"DeStefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinnasamy","family":"Elango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Andisik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giane","family":"Sumner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan C.","family":"Irvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Torri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Partridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"993_CR1","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1056\/NEJMoa011931","volume":"346","author":"N Casadevall","year":"2002","unstructured":"Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian J-J, Martin-Dupont P, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469\u201375. https:\/\/doi.org\/10.1056\/NEJMoa011931.","journal-title":"N Engl J Med"},{"issue":"14","key":"993_CR2","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"GM Bartelds","year":"2011","unstructured":"Bartelds GM, Krieckaert CLM, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JWR, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305(14):1460\u20138. https:\/\/doi.org\/10.1001\/jama.2011.406.","journal-title":"JAMA"},{"issue":"1\u20132","key":"993_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2004.06.002","volume":"289","author":"AR Mire-Sluis","year":"2004","unstructured":"Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods. 2004;289(1\u20132):1\u201316. https:\/\/doi.org\/10.1016\/j.jim.2004.06.002.","journal-title":"J Immunol Methods"},{"issue":"5","key":"993_CR4","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","volume":"48","author":"G Shankar","year":"2008","unstructured":"Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal. 2008;48(5):1267\u201381. https:\/\/doi.org\/10.1016\/j.jpba.2008.09.020.","journal-title":"J Pharm Biomed Anal"},{"key":"993_CR5","unstructured":"US Food and Drug Administration. Immunogenicity assessment for therapeutic protein products. Guidance for industry. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). 2014. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/immunogenicity-assessment-therapeutic-protein-products. Accessed 09 Aug 2024."},{"key":"993_CR6","unstructured":"European Medicines Agency. Guideline on immunogenicity assessment of therapeutic proteins. Committee for Medicinal Products for Human Use. 2017. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf. Accessed 09 Aug 2024"},{"key":"993_CR7","unstructured":"US Food and Drug Administration. Immunogenicity testing of therapeutic protein products - developing and validating assays for anti-drug antibody detection. Guidance for industry. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). 2019. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug. Accessed 09 Aug 2024."},{"issue":"11","key":"993_CR8","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJMoa074943","volume":"358","author":"CH Chung","year":"2008","unstructured":"Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and ige specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008;358(11):1109\u201317. https:\/\/doi.org\/10.1056\/NEJMoa074943.","journal-title":"N Engl J Med"},{"issue":"3","key":"993_CR9","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/jcph.818","volume":"57","author":"S Agrawal","year":"2017","unstructured":"Agrawal S, Statkevich P, Bajaj G, Feng Y, Saeger S, Desai DD, et al. Evaluation of immunogenicity of nivolumab monotherapy and its clinical relevance in patients with metastatic solid tumors. J Clin Pharmacol. 2017;57(3):394\u2013400. https:\/\/doi.org\/10.1002\/jcph.818.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"993_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s40425-019-0663-4","volume":"7","author":"MJH van Vugt","year":"2019","unstructured":"van Vugt MJH, Stone JA, De Greef RHJMM, Snyder ES, Lipka L, Turner DC, et al. Immunogenicity of pembrolizumab in patients with advanced tumors. J Immunother Cancer. 2019;7(1):212. https:\/\/doi.org\/10.1186\/s40425-019-0663-4.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"993_CR11","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1001\/jamaophthalmol.2023.2260","volume":"141","author":"SJ Woo","year":"2023","unstructured":"Woo SJ, Bradvica M, Vajas A, Sagong M, Ernest J, Studnicka J, et al. Efficacy and safety of the aflibercept biosimilar sb15 in neovascular age-related macular degeneration: a phase 3 randomized clinical trial. JAMA Ophthalmol. 2023;141(7):668\u201376. https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.2260.","journal-title":"JAMA Ophthalmol"},{"key":"993_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jpba.2012.10.027","volume":"74","author":"RJ Kubiak","year":"2013","unstructured":"Kubiak RJ, Zhang L, Zhang J, Zhu Y, Lee N, Weichold FF, et al. Correlation of screening and confirmatory results in tiered immunogenicity testing by solution-phase bridging assays. J Pharm Biomed Anal. 2013;74:235\u201345. https:\/\/doi.org\/10.1016\/j.jpba.2012.10.027.","journal-title":"J Pharm Biomed Anal"},{"issue":"23","key":"993_CR13","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.4155\/bio-2017-0185","volume":"9","author":"M Starcevic Manning","year":"2017","unstructured":"Starcevic Manning M, Kroenke MA, Lee SA, Harrison SE, Hoofring SA, Mytych DT, et al. Assay signal as an alternative to titer for assessment of magnitude of an antidrug antibody response. Bioanalysis. 2017;9(23):1849\u201358. https:\/\/doi.org\/10.4155\/bio-2017-0185.","journal-title":"Bioanalysis"},{"issue":"4","key":"993_CR14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1208\/s12248-022-00728-8","volume":"24","author":"M Starcevic Manning","year":"2022","unstructured":"Starcevic Manning M, Hassanein M, Partridge MA, Jawa V, Mora J, Ryman J, et al. Comparison of titer and signal to noise (s\/n) for determination of anti-drug antibody magnitude using clinical data from an industry consortium. AAPS J. 2022;24(4):81. https:\/\/doi.org\/10.1208\/s12248-022-00728-8.","journal-title":"AAPS J"},{"key":"993_CR15","volume-title":"Assay development for immunogenicity testing of therapeutic proteins. Draft guidance. Center for Drug Evaluation and Research (CDER)","author":"US Food and Drug Administration","year":"2009","unstructured":"US Food and Drug Administration. Assay development for immunogenicity testing of therapeutic proteins. Draft guidance. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER); 2009."},{"issue":"3","key":"993_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1208\/s12248-023-00806-5","volume":"25","author":"J Garlits","year":"2023","unstructured":"Garlits J, McAfee S, Taylor JA, Shum E, Yang Q, Nunez E, et al. Statistical approaches for establishing appropriate immunogenicity assay cut points: impact of sample distribution, sample size, and outlier removal. AAPS J. 2023;25(3):37. https:\/\/doi.org\/10.1208\/s12248-023-00806-5.","journal-title":"AAPS J"},{"issue":"3","key":"993_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.tjem.2018.08.001","volume":"18","author":"H Akoglu","year":"2018","unstructured":"Akoglu H. User\u2019s guide to correlation coefficients. Turk J Emerg Med. 2018;18(3):91\u20133. https:\/\/doi.org\/10.1016\/j.tjem.2018.08.001.","journal-title":"Turk J Emerg Med"},{"issue":"5","key":"993_CR18","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1208\/s12248-017-0107-3","volume":"19","author":"V Devanarayan","year":"2017","unstructured":"Devanarayan V, Smith WC, Brunelle RL, Seger ME, Krug K, Bowsher RR. Recommendations for systematic statistical computation of immunogenicity cut points. AAPS J. 2017;19(5):1487\u201398. https:\/\/doi.org\/10.1208\/s12248-017-0107-3.","journal-title":"AAPS J"},{"issue":"17\u201318","key":"993_CR19","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1080\/17576180.2024.2376949","volume":"16","author":"J Goodman","year":"2024","unstructured":"Goodman J, Cowan KJ, Golob M, Nelson R, Baltrukonis D, Bloem K, et al. Re-thinking the current paradigm for clinical immunogenicity assessment: an update from the discussion in the European bioanalysis forum. Bioanalysis. 2024;16(17\u201318):905\u201313. https:\/\/doi.org\/10.1080\/17576180.2024.2376949.","journal-title":"Bioanalysis."},{"issue":"1","key":"993_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4155\/bio-2023-0152","volume":"16","author":"D Guerrieri","year":"2023","unstructured":"Guerrieri D, Horvat M, Fan J, Wang J, Lemke L, Richter OV, et al. Signal-to-noise ratio to assess magnitude, kinetics and impact on pharmacokinetics of the immune response to an adalimumab biosimilar. Bioanalysis. 2023;16(1):33\u201348. https:\/\/doi.org\/10.4155\/bio-2023-0152.","journal-title":"Bioanalysis"},{"issue":"16","key":"993_CR21","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","volume":"376","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW, et al. Lipid-reduction variability and antidrug-antibody formation with bococizumab. N Engl J Med. 2017;376(16):1517\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1614062.","journal-title":"N Engl J Med"},{"issue":"5","key":"993_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1208\/s12248-023-00846-x","volume":"25","author":"F McCush","year":"2023","unstructured":"McCush F, Wang E, Yunis C, Schwartz P, Baltrukonis D. Anti-drug antibody magnitude and clinical relevance using signal to noise (s\/n): Bococizumab case study. AAPS J. 2023;25(5):85. https:\/\/doi.org\/10.1208\/s12248-023-00846-x.","journal-title":"AAPS J"},{"key":"993_CR23","doi-asserted-by":"publisher","first-page":"1466372","DOI":"10.1080\/17576180.2024.2376949","volume":"15","author":"MA Kamal","year":"2024","unstructured":"Kamal MA, Kosloski MP, Lai C-H, Partridge MA, Rajadhyaksha M, Kanamaluru V, et al. Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis. Front Immunol. 2024;15:1466372. https:\/\/doi.org\/10.1080\/17576180.2024.2376949.","journal-title":"Front. Immunol."}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-024-00993-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-024-00993-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-024-00993-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T17:57:13Z","timestamp":1740506233000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-024-00993-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["993"],"URL":"https:\/\/doi.org\/10.1208\/s12248-024-00993-9","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]},"assertion":[{"value":"19 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors are employees of Regeneron Pharmaceuticals, Inc., and may hold stock and\/or stock options in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The views expressed in this article are those of the authors and do not reflect the official policy of Regeneron Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}],"article-number":"11"}}